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disrupting protein–protein interactions†
Jordan M. Fletcher, ‡a Katherine A. Horner, ‡bc Gail J. Bartlett, a
Guto G. Rhys, a Andrew J. Wilson *bc and Derek N. Woolfson *ade
Protein–protein interactions (PPIs) play pivotal roles in the majority of biological processes. Therefore,
improved approaches to target and disrupt PPIs would provide tools for chemical biology and leads for
therapeutic development. PPIs with a-helical components are appealing targets given that the secondary
structure is well understood and can be mimicked or stabilised to render small-molecule and
constrained-peptide-based inhibitors. Here we present a strategy to target a-helix-mediated PPIs that
exploits de novo coiled-coil assemblies and test this using the MCL-1/NOXA-B PPI. First, computational
alanine scanning is used to identify key a-helical residues from NOXA-B that contribute to the interface.
Next, these residues are grafted onto the exposed surfaces of de novo designed homodimeric or
heterodimeric coiled-coil peptides. The resulting synthetic peptides selectively inhibit a cognate MCL-1/
BID complex in the mid-nM range. Furthermore, the heterodimeric system aﬀords control as inhibition
occurs only when both the grafted peptide and its designed partner are present. This establishes proof of
concept for exploiting peptides stabilised in de novo coiled coils as inhibitors of PPIs. This dependence
on supramolecular assembly introduces new possibilities for regulation and control.Introduction
In healthy cells, proteins tend not to function as single entities
but rather as components of dynamic, multi-component
complexes. Thus, the function of a protein does not merely
relate to its underlying primary and tertiary structures but also
to the protein–protein interactions (PPIs) that it makes. In turn,
PPIs regulate the vast majority of biological processes, which
they do with exquisite control.1,2 For example, the roles of Myc,
Mad and related oncogenes in transcriptional control depends
on them making heterodimeric coiled-coil-based complexes
with Max.3 Likewise in disease, mutations to or changes in
expression levels of such components can lead to aberrant PPIs.
Therefore, eﬀorts to modulate PPIs have received increasing
attention within the chemical-biology and drug-discovery
communities;4–6 although our rudimentary understanding of, Cantock's Close, Bristol BS8 1TS, UK.
on@bristol.ac.uk
oodhouse Lane, Leeds LS2 9JT, UK
iology, University of Leeds, Woodhouse
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Chemistry 2018signalling pathways means that it is not always clear what
proteins to target to guarantee desired responses.7
The use of synthetic molecules to modulate PPIs is attractive
for multiple reasons, including: in principle, they are orthog-
onal to the natural components being targeted; they can be used
to facilitate temporal and titratable control over protein func-
tion to illuminate biological processes in healthy and diseased
states; and chemical probes in particular can serve as spring-
boards for subsequent drug discovery and development.8,9 That
said, the design or engineering of genuinely competitive
synthetic inhibitors of a PPI requires projection of recognition
moieties and functional groups into what are oen relatively
at, large protein surfaces. As a result, progress in this area has
proven challenging.4–6 Similarly, the ability to emulate and
exploit nature's regulatory mechanisms using synthetic mole-
cules—e.g., to rewire signalling processes,10 control local-
isation11 or initiate degradation12—is still in its infancy.
a-Helix-mediated PPIs have emerged as a class that is
amenable to small-molecule inhibition.13–15 Considerable work
in this area has led to the elaboration of several generic
modalities for inhibition,16 including the use of mini17 and
designed proteins,18–20 stapled peptides21–27 and foldamers,28,29
all of which mimic the topology of the helix; the development of
proteomimetics30–32 that mimic the topography of a helix; and
protein graing.33,34 Such constrained peptides, which exploit
the functionally optimised specicity and selectivity of natural
peptide motifs, are attractive from a recognition perspective as
pre-organising such motifs in a recognition competentChem. Sci.
Fig. 1 Coiled coils, MCL-1 structures and design rationale for the
current study. (A) Helical-wheel diagram depicting a parallel dimeric
coiled coil. Hydrophobic residues at positions a and d are shaded black
and ﬂanking residues at e and g are shaded grey. (B) The archetypal
parallel, homodimeric coiled coil GCN4 (ref. 50) (PDB code: 2ZTA). (C)
Solution structure of the MCL-1 : NOXA-B complex63 (PDB: 2JM6).
The NOXA-B ligand is coloured pink, and the MCL-1 protein shaded
grey. (D) Crystal structure of the de novo designed homodimeric
coiled coil, CC-Di42 (PDB: 4DZM). (E) Schematic depicting the struc-
ture of a coiled-coil heterodimer composed of an acidic strand (red)
and a basic strand (blue). (F–H) Representations of proposed MCL-
1 : coiled coil assemblies generated by aligning backbone atoms of
one helix from the coiled coil with those of the NOXA-B peptide.
Alignments and images were generated using PyMOL [http://
pymol.org/2/].
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View Article Onlineconformation may enhance aﬃnity;35 and the constraint may
bring benets such as improved stability to proteolysis36 and
cellular uptake,37 which can be limiting with linear-peptide-
based drugs.
Advances in methods to constrain peptides in helical
conformations have led to considerable success in targeting
diverse PPIs21,23 and progress towards clinical applications.35
Despite these advances, most approaches deviate from natural,
proteinogenic amino acids invariably resulting in increased
chemical complexity and, in turn, increasing the diﬃculty and
cost of synthesis. Moreover, the constraining moiety itself
potentially introduces non-canonical binding modes38 and oﬀ-
target toxicity (e.g., through cell-membrane interactions).39 In
addition, with only a few exceptions—e.g., photoresponsive40
and reversible41 constraints—current methods are not
amenable to introducing regulatory control mechanisms such
as those present in biological systems, i.e., conformational
switching.
To address some of these issues, we reasoned that a-helical
coiled coils might provide suitable scaﬀolds for presenting
motifs to disrupt PPIs. In the rst aspect of our concept—which
involves graing a motif onto the outer, solvent-exposed face of
a de novo homodimeric coiled coil—two peptide helices eﬀec-
tively template and stabilise each other. In the second—which
uses a de novo heterodimeric coiled coil with only one of the
peptides decorated with the motif—an element of control is
introduced, as the graed peptide is only stabilised and
competent to interfere with the PPI with its partner present.
Others have reported a similar system based on the natural
homodimeric leucine zipper, GCN4, from yeast.34 Here we
expand on this theme, employing de novo designed coiled coils
over which we have considerable control in directing oligomer
state, partner specicity and stability through rational peptide
design.42,43
Coiled coils are one of the most abundant, extensively
studied, and well understood of all protein folds.44,45 Their
sequences oen have patterns of hydrophobic (H) residues
spaced alternately three and four residues apart with inter-
vening polar (P) residues to give characteristic 7-residue, or
heptad repeats, HPPHPPP, usually denoted abcdefg. When
congured into an a helix, this places the H residues at a and
d positions resulting in a seam that drives helical association
(Fig. 1). As proposed by Crick,46 the structural characteristic of
coiled coils is “knob-into-holes” packing in which residues at
a and d on one helix dock into diamond-shaped constellations
formed by residues at d1, g1, a & d and a, d, e & a+1 of
a neighbouring helix. Side chains at e and g ank this hydro-
phobic core and are frequently complementary charged resi-
dues leading to inter-helical salt bridges. The remaining
residues at the b, c, and f positions are usually not part of the
helix interface and oﬀer scope to be decorated with residues of
choice. This understanding of coiled-coil assembly has led to
sequence-to-structure relationships and computational
methods to facilitate the reliable de novo design of a wide variety
of coiled coils. These include homo-dimers through hep-
tamers,42,47–50 heteromeric complexes,43,51–55 and parallel or
antiparallel topologies.56,57Herein, we use parallel homodimericChem. Sci.(Fig. 1D) and heterodimeric (Fig. 1E) coiled coils as scaﬀolds for
presenting binding residues.
To test our hypothesis that coiled coils could be used to
scaﬀold motifs to inhibit PPIs, we sought a model interaction in
which a relatively long and straight helical ligand binds its
cognate protein along a deep groove. Of the clinically relevant
helix-mediated PPIs,13,58 we chose the MCL-1/NOXA-B interac-
tion (Fig. 1C). MCL-1 is an anti-apoptotic member of the BCL-2
family of PPIs that collectively determine cellular response to
pro and anti-apoptotic stimuli.59 The canonical BCL-2 interac-
tion involves docking of the BH3 domain from a family member
in a helical conformation to a cle on a multi-BH-domain
partner.60 MCL-1 is a particularly attractive target because of
its role in multiple cancers and its immunity to inhibition by
other BCL-2 family inhibitors.61 As a result, chemical probesThis journal is © The Royal Society of Chemistry 2018
Table 1 Designed NOXA-B/coiled-coil hybrid pep-tides. Key: resi-
dues of NOXA-B identiﬁed to bind MCL-1 are underlined. These are
then serially grafted onto the de novo coiled-coil sequences (CC-Di,
green; CC-Di-A, red; CC-Di-B, blue) as indicated in underlined bold
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View Article Onlinehave been developed to validate it as a target for preclinical
studies.62
Here we target the MCL-1/NOXA-B interaction to examine if
a-helical ligands could be redesigned to be stable, potent
inhibitors of PPIs without recourse to using non-proteinogenic
amino acids and specialist synthetic methodologies. First, we
perform a computational alanine scan to identify residues
present in NOXA-B critical for MCL-1 binding. Next, we gra
these residues onto the outer face (b, c, and f sites) of the de novo
coiled-coil homodimer, CC-Di (Fig. 1F), and on each peptide of
the obligate heterodimer, CC-Di-AB (Fig. 1G and H).43 The
decorated coiled coils are characterised by solution-phase
biophysical techniques, and MCL-1 binding is determined by
uorescence anisotropy competition assays. In this way, we
show that inhibition requires stabilisation of the helical
conformation of the synthetic ligand, and that it depends on
coiled-coil formation in a manner that mirrors regulatory
control observed in cellular processes. Crucially, the graed
ligands retain the selectivity prole of NOXA-B and do not
inhibit interactions of the related BCL-2 family member, BCL-
xL, and an unrelated helix mediated PPI, hDM2/p53.Results and discussion
Designing coiled-coil dimers to mimic NOXA-B
To determine the most-important residues of NOXA-B for
binding MCL-1, an NMR structure of MCL-1/NOXA-B (PDB ID:
2JM6) was probed by computational alanine (Ala) scan using
Robetta.59 Briey, this denes the interface between partners by
calculating the contribution that each residue makes to the in
silico interfacial free energy relative to an Ala mutant at that
position. Arbitrarily, residues with DDG of >1.0 kcal mol1 were
considered signicant contributors to binding (Fig. 2).64 These
included a central cluster of residues—Leu11, Arg12, Ile14,
Asp16, and Val18—which we refer to as the short motif (S); and
Leu4, Leu25 and Asn26, which, together with S, comprise anFig. 2 Computational alanine scan examining MCL-1/NOXA-B inter-
action using Robetta.64 Residues with a calculated DDG of
>1 kcal mol1 are coloured pink. The Gly residue, conserved across
BCL-2 family members, is also highlighted (*).
This journal is © The Royal Society of Chemistry 2018extended motif (E1). Glycine (Gly) residues are not included in
such analysis because mutation to Ala introduces bulk and may
not be tolerated without changes to the backbone. Inspection ofFig. 3 CD spectra (left) and thermal unfolding curves (right) for coiled
coils, and coiled coil–NOXA-B hybrid peptides. (A & B) CC-Di (pale
green), CC-Di_S (lime), CC-Di_E1 (green), CC-Di_E2 (olive). (C & D) CC-
Di-A (pink), CC-Di-B (cyan), CC-Di-A : CC-Di-B mixture (purple). (E & F)
CC-Di-A_S (red), CC-Di-B (cyan), CC-Di-A_S : CC-Di-B mixture
(brown). (G & H) CC-Di-A (pink), CC-Di-B_S (blue), CC-Di-A : CC-Di-
B_S mixture (indigo). For heteromeric assemblies (i.e. Panels C–H) the
theoretical spectra expected should the pairs of peptides not interact are
depicted by grey dashes. Conditions: all experiments were performed in
phosphate-buﬀered saline (PBS; pH 7.4) at 50 mM concentration of each
peptide. Equilibrium CD spectra were recorded at 20 C.
Chem. Sci.
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View Article Onlinethe MCL-1/NOXA-B structure revealed close packing of Gly15
against MCL-1, and the residue is highly conserved in BH3
domains across BCL-2 family members.65 Therefore, this
residue was retained in the designs depicted in Table 1.
The de novo designed coiled-coil peptide CC-Di (Fig. 1B; PDB:
4DZM)42 was chosen as the scaﬀold for iterative functional design
for the following reasons: rst, CC-Di has been extensively char-
acterised;42 second, the de novo design centres on the g, a, d and e
sites of the heptad repeat, leaving residues at b, c and f free for
functionalisation; third, related to the previous point, altering the
salt-bridge patterning at g and e allows this homodimeric coiled
coil to be converted to an obligate heterodimer comprising
peptides CC-Di-A and CC-Di-B (Fig. 1E);43 fourth, it does not suﬀer
from the oligomer state promiscuity observed for other commonly
used coiled coils such as GCN4-p1;66 and nally, the X-ray crystal
structure of CC-Di (PDB: 4DZM)42 reveals a high superhelical pitch
of 226 A˚, which renders the helices relatively straight (Fig. 1D). For
the design process, we graed the identied binding residues
together with the conserved Gly from NOXA-B onto the sequence
of CC-Di to give a series of hybrid designs (Table 1). The sequences
of the NOXA-B peptide and CC-Di were aligned manually such
that the binding residues from the former overlaid predominantly
the b, c and f positions of the latter. This process furnished several
peptides: CC-Di_S, designed to form a homodimeric coiled coilTable 2 Summary of biophysical data
Peptide(s) Schematic
MRE222
a (deg cm2 dmol re
(% helicity)68
CC-Di 31.650 (90%)
CC-Di_S 30.930 (88%)
CC-Di_E1 28.259 (81%)
CC-Di_E2 23.091 (66%)
CC-Di-A 6577 (19%)
CC-Di-A_S 4910 (14%)
CC-Di-B 25.088 (71%)
CC-Di-B_S 16.247 (46%)
CC-Di-A + CC-Di-B 29.154 (82%)
CC-Di-A_S + CC-Di-B 27.395 (78%)
CC-Di-A + CC-Di-B_S 24.490 (69%)
a Mean residue ellipticity values at 222 nm from circular dichroism (CD) s
thermal denaturation curves determined by monitoring the MRE222 betwe
analytical ultracentrifugation and expressed relative to monomer molecula
Chem. Sci.with the short motif presented on both of its outer surfaces; CC-
Di_E1, to present two copies of the extended motif; and CC-
Di_E2, to present the extended motifs plus two additional resi-
dues, Glu7 and Asn19, from NOXA-B that each scored DDG values
of 0.96 kcal mol1 in the computational alanine scan (Fig. 2). N.B.,
to incorporate Glu7, we switched the second residue to Lys to
maintain the intermolecular salt bridge in the rst heptad of this
coiled coil. To add control over helix formation and scaﬀold
assembly, and to reduce the number of congured binding sites
to one per assembly, we also designed two heterodimeric systems:
CC-Di-A_S, which is an acidic peptide containing the short motif,
designed to partner peptide CC-Di-B; and CC-Di-B_S, a basic
peptide with the same gra that should partner peptide CC-Di-A
(Table 1).
The designed peptides were synthesised by microwave-
assisted Fmoc solid-phase techniques, puried by RP-HPLC,
and conrmed by mass spectrometry (ESI Fig. S1 and S3†).
The redesigned peptides fold as a-helical dimers in solution
Circular dichroism (CD) spectroscopy was used to examine the
secondary structure and stability of designed peptides in solu-
tion (Fig. 3, Table 2). Like the parent CC-Di, at 50 mM the hybrid
peptides CC-Di_S, CC-Di_E1, and CC-Di_E2 exhibited CD
spectra typical of highly a-helical structures (Fig. 3A). Ons1),
TM
b (C) Oligomer statec IC50 MCL-1/BID (mM)
75 1.96 No response
53 1.74 26  1
48 1.93 0.7  0.05
30 1–2d 0.09  0.005
NA (<0) NA No response
NA (<0) NA 21  0.4
38 ND No response
27 ND No response
91 ND Not tested
74 1.83 44  1
71 1.9 40  2
pectra recorded at 20 C in PBS at 50 mM of each peptide. b Midpoints of
en 5 and 90 C ramped at 40 C h1. c Oligomeric states determined by
r mass. d Data for CC-Di_E2 were tted to monomer–dimer equilibrium.
This journal is © The Royal Society of Chemistry 2018
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
7 
A
ug
us
t 2
01
8.
 D
ow
nl
oa
de
d 
on
 9
/1
2/
20
18
 3
:3
3:
51
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinethermal denaturation, however, the hybrid peptides were found
to be destabilised with reduced midpoints (TM) of thermal
unfolding transitions relative to the parent (Fig. 3B, Table 2).
This is likely a consequence of the en bloc changes to the
sequence including the loss of a g–e salt bridge in heptad 2; and
the introduction of several helix-destabilising residues,67 in
particular the Gly residue at position 15. Indeed, across the
series of homodimeric peptides prepared for this study, the TM
values consistently fell as more residue changes were made
(Table 2). Regarding the heterodimeric designs, both CC-Di-A
and CC-Di-A_S were largely unfolded, whereas the two CC-Di-
B-based peptides showed some a helicity, but these were
unstable to heating with TM values of <40 C (Fig. 3C–H
and Table 2). However, mixing the CC-Di-A variants with the
CC-Di-B-based partners (at 50 mM of each peptide) gave
increased a helicities and thermal stabilities (Fig. 3C–H and
Table 2); although, again, these were lower than for the parent
CC-Di-A : CC-Di-B mixture. Similar results were obtained when
these analyses were performed at 1 mM peptide concentration,
though with expected further drops in TM (ESI Table S5†).
We used sedimentation-equilibrium analytical ultracentri-
fugation (AUC) to determine if the graing of NOXA-B residues
into the de novo coiled coils, which are designed to be
dimeric,42,43 aﬀected their oligomeric state (Table 2, Fig. S6†).
The AUC data for the CC-Di_S and CC-Di_E1 peptides and the
hetero-combinations CC-Di-A : CC-Di-B_S and CC-Di-A_S : CC-
Di-B all tted to single ideal species and returned weights
consistent with dimeric assemblies (Table 2). Data recorded at
20 C for the most extensively decorated peptide, CC-Di_E2,
tted to monomer–dimer equilibrium returning a KD of 7.26
mM. This is consistent with results obtained from thermal
denaturation experiments monitored by CD (TM¼ 16 C at 1 mM
peptide concentration; ESI Table S5†).
In summary, the biophysical analyses conrm that upon
graing NOXA-B-derived MCL-1-binding residues onto the de
novo designed coiled-coil sequences the peptides remain folded
dimers in solution at pH 7.4 and at least over the 1–50 mM range
of peptide concentrations.Fig. 4 Competitive-displacement assays of hybrid peptides inhibiting
the MCL-1/FITC BID interaction. (A) Titrations with the homodimeric
CC-Di variants (CC-Di (pale green squares), CC-Di_S (lime circles),
CC-Di_E1 (green upwards triangle), CC-Di_E2 (olive downwards
triangle)); (B) the heterodimer system with CC-Di-A decorated (CC-
Di-A_S (red circles), CC-Di-B (cyan squares), CC-Di-A_S : CC-Di-B
mixture (brown triangles)); and (C) the heterodimer system with CC-
Di-B decorated (CC-Di-A (pink circles), CC-Di-B_S (blue squares),
CC-Di-A : CC-Di-B_S mixture (indigo triangles)). Conditions: 150 nM
MCL-1, 25 nM FITC-BID, 21 C, Tris buﬀer (50 mM Tris, 150 mM NaCl,
pH 7.4) + 0.01% Triton-X-100.The decorated coiled-coil peptides displace a reporter peptide
from MCL-1
Fluorescence anisotropy (FA) competition assays were per-
formed to dene the potential inhibitory behaviour of the coiled
coil–NOXA-B hybrids towards MCL-1. In these experiments, the
decorated peptides—either individually for the CC-Di variants,
or paired for the CC-Di-A/B systems—were titrated against MCL-
1 preincubated with a uorescently labelled tracer peptide,
FITC-BID, which is derived from the wild-type BID BH3 domain
(Table S3†).24
As a control, the unmodied homodimeric coiled coil, CC-
Di, did not displace FITC-BID (Fig. 4A). By contrast, responses
were observed for all three decorated homodimeric coiled coils
indicating a specic binding event conferred by the NOXA-B-
binding residues graed onto the peptides. Moreover, the
half-maximal inhibitory concentrations (IC50) decreased
signicantly across the series CC-Di_S, CC-Di_E1, CC-Di_E2,This journal is © The Royal Society of Chemistry 2018indicating that the recognition surface of NOXA-B was being
increasingly mimicked. Indeed, incorporation of the larger
NOXA-B interface gave an inhibitory potency of z90 nM. ForChem. Sci.
Chemical Science Edge Article
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View Article Onlinecomparison, a truncated wild-type NOXA-B competitor peptide
yielded an IC50 of 375  22 nM (ESI Fig. S8b†). This demon-
strates the potential power of the graing strategy described
herein to deliver MCL-1 ligands that are comparable or superior
to BH3 domains. Crucially, the results imply that binding and
stabilisation of CC-Di_E2 to MCL-1 are co-operative; i.e., MCL-1
binding stabilises the coiled-coil assembly.Heterodimeric coiled coils provide control over binding
To gauge the relative importance of induced and pre-organised
a helicity, we extended the competition binding assays to the
designed heterodimers. We compared the binding of the
decorated peptides CC-Di-A_S and CC-Di-B_S alone and when
dimerised with their cognate undecorated partners CC-Di-B and
CC-Di-A, respectively (Fig. 4B and C).
First, and surprisingly, peptide CC-Di-A_S bound to MCL-1
appreciably with an IC50 of z20 mM (Fig. 4B, Table 2). More-
over, this binding was impaired two-fold in the presence of CC-
Di-B. We oﬀer the following explanation for this: rst, and in
contrast to the other peptides of this study, CC-Di-A and CC-Di-
A_S are expected to be highly anionic at neutral pH (charge
z7). This could augment binding through electrostatic
interactions as the solvent-exposed surface of MCL-1 isFig. 5 Selectivity assays of coiled-coil constructs against MCL-1/FITC-B
With CC-Di_E2 (A) and CC-Di-B_S + CC-Di-A (B). (C) Tabulated results fo
FITC-BID, and 150 nM hDM2, 25 nM Flu-p53.
Chem. Sci.somewhat basic around the NOXA-B binding groove (Fig. S7†).
Thus, there might be some electrostatic steering between the
highly acidic CC-Di-A_S and the MCL-1 target.69 In turn, this
might explain the reduced binding for the CC-Di-A_S : CC-Di-B
heterodimer as the highly basic CC-Di-B (anticipated charge at
neutral pHz +9) will eﬀectively neutralise or screen the anionic
character of CC-Di-A_S. Nonetheless, second, we can attribute
some of the binding of the isolated CC-Di-A_S peptide to the
graed NOXA-B residues as unmodied CC-Di-A does not bind
MCL-1 (Fig. 4C). Indeed, CC-Di-A_S possesses more MCL-1
binding residues than its nominally similarly decorated coun-
terparts CC-Di_S and CC-Di-B_S. Specically, and as part of the
CC-Di-A background design, CC-Di-A_S has glutamic acid (Glu)
at residue 7 (Table 1). This residue aligns with a Glu residue of
extended binding motif from NOXA-B (Fig. 2) being noted as
a possible contributor to binding in the computational alanine
scan (DDG ¼ 0.96 kcal mol1). This highlights the multi-
factorial nature of PPIs and that attention must be paid to all
such factors in inhibitor design.
By contrast, when NOXA-B residues were graed onto the
CC-Di-B component of the heterodimer the behaviour was as
designed: neither of the free peptides, CC-Di-B or CC-Di-B_S,
competed with FITC-BID for binding to MCL-1 (Fig. 4B and
C); however, when complemented by CC-Di-A, CC-Di-B_S boundID (squares), BCL-xL/FITC-BID (circles), and hDM2/Flu-p53 (triangles).
r all selectivity displacement assays. Conditions: 150 nM BCL-xL, 25 nM
This journal is © The Royal Society of Chemistry 2018
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View Article Onlinewith IC50 comparable to the CC-Di_S homodimer (Fig. 4C, Table
2). Thus, in this case non-covalent interaction with CC-Di-A
biases CC-Di-B_S in favour of an a-helical and bioactive
conformation, in eﬀect entropically pre-organising it to
enhance target binding aﬃnity.The design constructs bind and inhibit MCL-1 selectively
Finally, we tested the extent to which the de novo coiled coil–
NOXA-B hybrids that bound MCL-1 did so selectivity (Fig. 5). To
do this, we employed two related protein targets, BCL-xL and
hDM2.15,70–72 Like MCL-1, BCL-xL is a multi-domain anti-
apoptotic BCL-2 family member. MCL-1 and BCL-xL engage in
both selective and promiscuous interactions with pro-apoptotic
modulators and executioners within the BCL-2 family. However,
unlike MCL-1, BCL-xL does not recognise NOXA-B, whilst both
proteins recognise BID and other BH3 sequences.73,74 The
diﬀerent selectivity preferences of BCL-xL and MCL-1, their
close relationship within the BCL-2 family, and the fact that
both could be used in the competitive uorescence anisotropy
experiments using FITC-BID, made BCL-xL a particularly
attractive and stringent test of selectivity. hDM2 is a negative
regulator of the transcription factor p53,70,71 and was also
included as an interesting test of selectivity as p53 has been
shown to interact with both MCL-1 and BCL-xL through a tran-
scription-independent mechanism.75
Data (not shown) from the titration of the homodimeric CC-
Di_S against BCL-xL/FITC-BID were inconclusive, and no clear
displacement/binding curve was apparent. We attribute this to
aggregation of the homodimer with other assay components,
possibly with the labelled reporter peptide, at higher concen-
trations. However, titrating CC-Di_E1 and CC-Di_E2 against
either BCL-xL/FITC-BID or hDM2/Flu-p53 gave no observable
inhibitory response (Fig. 5A, C and S8e & g†). Notably, CC-Di_E2
was titrated to a maximum concentration of 150 mM, demon-
strating at least 2000-fold selectivity towards MCL-1 over BCL-xL
and hDM2. Similarly, the heterodimer combination that dis-
placed FITC-BID from MCL-1, CC-Di-B_S + CC-Di-A, did not
inhibit either BCL-xL or hDM2 (Fig. 5B).
CC-Di-A_S and the CC-Di-A_S : CC-Di-B combination both
inhibited hDM2/Flu-p53, and the former showed weak binding
with BCL-xL/FITC-BID (Fig. 5C and S8e & g†). This reveals poor
selectively by the decorated CC-Di-A_S peptide whether alone or
if complexed CC-Di-B. Together with the response noted above
in the assay with MCL-1/FITC-BID, this indicates further that
CC-Di-A_S binds non-specically to diﬀerent protein targets. In
both cases, the binding of unfolded CC-Di-A_S was stronger
than with the heterodimer combination. As noted for MCL-1,
the binding sites of BCL-xL and hDM2 are also slightly basic.Conclusion
Taken together, these data demonstrate the utility of de novo
designed coiled coils as scaﬀolds for PPI inhibitors. By graing
residues from the helical motif of NOXA-B found at the natural
protein–protein interface onto homo and heterodimeric de novo
coiled coils, selective inhibition of MCL-1/FITC-BID has beenThis journal is © The Royal Society of Chemistry 2018achieved over BCL-xL/FITC-BID and hDM2/Flu-p53. The inhib-
itory potency depends on the extent of graing; i.e., introducing
more hotspot residues gives greater potency. Moreover, as
demonstrated through a heterodimeric coiled-coil system,
inhibition requires the presence of both partners demon-
strating supramolecular control over folding, presentation, and
binding by the graed motif.
In a study by others,34 p53 hotspot residues have been graf-
ted onto the natural GCN4 leucine zipper and shown to inhibit
the hDM2/p53 interaction, including, upon addition of cell-
penetrating functionality to the graed peptide, in cellular
models.34 Using such a naturally derived coiled coil can carry
risks. For instance, GCN4 variants show a variety of coiled-coil
oligomer states.66 The de novo designed systems introduced
herein have several distinct advantages over naturally derived
coiled coils: (i) they are structurally well-dened dimeric coiled-
coil templates; (ii) they can be congured as a homo or heter-
odimer, thus allowing control over the stoichiometry of pepti-
de : protein assemblies; (iii) the potency of inhibition can be
readily controlled by the extent of graing; (iv) coiled-coil
formation is required for inhibition, i.e., one helix acts as
a non-covalent staple to promote helicity of the second helix
bearing the PPI motif; and (v) inhibition of the target PPI is
selective.
There are potential pitfalls with de novo systems, of course.
For example, here we note promiscuous, non-selective binding
to targets by the decorated variants of the acid peptide, CC-Di-A.
We attribute this to a combination of the peptides harbouring
a latent binding site plus having some electrostatic comple-
mentarity to regions around the target sites. However, as we
illustrate by decorating the basic peptide, with de novo peptides
this is can be remedied by redesign.
Our study establishes that de novo designed peptides from
a synthetic-biology toolkit42,43 can be augmented with natural
motifs to modulate PPIs through supramolecular assembly. We
envisage that this capability might be harnessed in other ways.
For example, to direct target proteins to form new or alternative
quaternary interactions mediated by coiled coils decorated with
two or more diﬀerent binding motifs. This could be used to
inhibit two or more PPIs simultaneously, or to bring together
target proteins to act together or on each another. This will be
the focus of our future studies.Experimental
Computational alanine scan
The rst model in the NMR structure of MCL-1/NOXA-B (PDB:
2JM6) was used to carry out a computational alanine scan on the
Robetta64 alanine scanning server (http://www.robetta.org).
Contributions of >1 kcal mol1 to the binding interface were
recorded as signicant.Synthesis of coiled-coil peptides
Rink amide Chem-Matrix resin was purchased from PCAS Bio-
matrix Inc. (St-Jean-sur-Richelieu, Canada). Fmoc-L-amino acids
and dimethylformamide (DMF) were obtained from AGTCChem. Sci.
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View Article OnlineBioproducts (Hessle, UK); all other reagents were obtained from
Sigma-Aldrich (Gillingham, UK). Peptides were prepared by
standard Fmoc solid-phase techniques on a Liberty Blue
microwave peptide synthesiser (CEM; Mathews, NC, U.S.A.)
using repeated steps of amino acid coupling and Fmoc depro-
tection. Coupling was achieved by diisopropylcarbodiimide
(DIC)/6-chloro-1-hydroxybenzotriazole (Cl-HOBt) activation in
DMF on H-Rink Amide (ChemMatrix®) resin (0.1 mmol). Fmoc
deprotection was performed by treatment with 20%morpholine
in DMF. For peptides containing an aspartic acid residue, 5%
formic acid was added to the deprotection solution to minimise
aspartimide formation during chain elongation.76 Following
assembly, the N-terminus of each peptide was acetylated (acetic
anhydride (3 eq.), DIPEA (4.5 eq.) in DMF for 30 min). Cleavage
of the peptide from the resin, and concomitant removal of
sidechain protection, was achieved by treating the resin-
attached peptides with a cocktail of triuoroacetic acid (TFA)/
H2O/triisopropylsilane (38 : 1 : 1 v/v, 10 mL) for 3 h at RT. Resin
was removed by ltration before the peptide was precipitated by
the addition of ice-cold diethyl ether and centrifuged. Diethyl
ether was then decanted, and the peptide pellet dissolved in
1 : 1 H2O/MeCN, frozen and lyophilised. Peptides were puried
by HPLC (using a Kromatek (semi-micro, 5 mm, 100 A˚, 10 mm ID
 150 mm L) C18 reverse-phase column) employing a linear
gradient (at 3 mL min1) of 20% to 80% MeCN in water (each
containing 0.1% TFA). Fractions thought to contain the peptide
of interest were analysed by analytical reverse-phase HPLC
(Phenomenex Kinetex C18 column (5 mm particle, 4.6 
100 mm)) and MALDI-TOF mass spectrometry. Those fractions
found to contain exclusively the product of interest were pooled
and lyophilised. Analytical HPLC of the nal product revealed
a purity of >95% (Fig. S3†). Successful synthesis was conrmed
by mass spectrometry (see Fig. S5 and Table S1†).
Synthesis of monomeric native peptides and analogues
Fluorescently labelled peptide FITC-BID was prepared as
previously described.24 Flu-p53 was purchased from Peptide
Protein Research Ltd. (Bishops Waltham, UK). wt NOXA-B was
prepared in house, the details of which are provided in the ESI,†
with successful synthesis conrmed by ESI-MS (Fig. S2†) and
HPLC (Fig. S4†). Sequences of FITC-BID, Flu-p53, and wt NOXA-
B peptides are provided in Table S2.†
Protein expression and purication
MCL-1,24 Bcl-xL,24 and hDM2 (ref. 77) proteins were expressed
and puried as described previously. High-resolution mass-
spectrometry data are provided in Fig. S5 & Table S3.†
Circular dichroism spectroscopy
CD spectra were collected using a JASCO J810 spectropolarimeter
coupled to a Peltier temperature controller. Peptide-containing
solutions were freshly prepared in PBS (pH 7.4) with concentra-
tions calculated from UV absorption at 280 nm (3(Tyr) ¼ 1280
mol1 cm1).78 Samples were examined at 50 mM concentration
for lone peptides and 50 + 50 mM for two peptide heterodimeric
examples, in a 1 mm quartz cuvette. Homodimeric, andChem. Sci.heterodimeric pairs of peptides, found to be both folded and to
bind MCL-1, were further examined at 1 mM in a 1 cm quartz
cuvette. Thermal denaturation experiments were conducted by
ramping temperature from 5 to 90 C at 40 C h1. Full spectra
(260–190 nm, 5 scans) were recorded at 5 C and 20 C, while the
CD signal at 222 nm was recorded across the full temperature
range at 1 C intervals (1 nm interval, 1 nm bandwidth, 16 s
response time). Raw data was normalised for peptide concen-
tration & length, and cuvette pathlength to give mean residue
ellipticity (MRE; deg cm2 dmol res1).
Analytical ultracentrifugation
Analytical ultracentrifugation (AUC) was performed at 20 C in
a Beckman Proteomelab XL-A or Beckman Proteomelab XL-I
analytical ultracentrifuge using an An-60 Ti rotor and 2-
channel centrepieces. Sedimentation equilibrium experiments
were prepared in PBS (137 mM NaCl, 2.7 mM KCl, 8.2 mM
Na2HPO4 and 1.8 mM KH2PO4) at 50 mM peptide concentration
for homomeric assemblies and 50 mM peptide concentration of
both peptides for heteromeric assemblies and to 120 mL. The
reference channel was loaded with 130 mL of PBS solution.
Equilibrium distributions were measured twice per speed, in 4
krpm increments, and with rotor speeds from 40 to 60 krpm.
Data were tted to single ideal species models using Ultrascan II
(http://www.ultrascan.uthscsa.edu). A better t for CC-Di_E2
data was found using monomer–dimer equilibrium with
a xed monomer mass. 95% condence limits were obtained by
Monte Carlo analysis of the ts. The partial specic volume for
each of the peptides and the buﬀer density were calculated
using Ultrascan II.
Fluorescence anisotropy
Assays were carried out in 96 or 384 well Optiplates and were
scanned using a Perkin Elmer EnVision™ 2103 MultiLabel plate
reader. Fluorescein-labelled peptides were examined using an
excitation and emission wavelength of 480 nm and 535 nm
respectively (dichroic mirror 505 nm). All assays were performed
in Tris buﬀer: (50 mM Tris, 150 mMNaCl, pH 7.4), with additives
stipulated. Direct titrations and competition assays were cong-
ured and performed using minor modications to those
described previously,24 and are detailed in full in the ESI.†
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